Riociguat replacing PDE5i therapy
Research payments
$307,903
Through program year 2023, $307,903 in research payments was reported against Riociguat replacing PDE5i therapy, across 90 payments, paid by Bayer HealthCare Pharmaceuticals Inc..
- Paid by
- Bayer HealthCare Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $18,207 | 3 |
| 2021 | Research | $18,131 | 10 |
| 2020 | Research | $156,216 | 41 |
| 2019 | Research | $115,349 | 36 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Franck Rahaghi Weston, FL Named on 11 payments
- Christina Migliore Newark, NJ Named on 9 payments
- Shilpa Desouza Mineola, NY Named on 7 payments
- Roxana Sulica New York, NY Named on 7 payments
- Shilpa Johri Richmond, VA Named on 6 payments
- Roblee Allen Sacramento, CA Named on 5 payments
- Rana Awdish Detroit, MI Named on 4 payments
- R White Rochester, NY Named on 3 payments
- Samuel Allen Troy, MI Named on 3 payments
- Trushil Shah Dallas, TX Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.